Update on the outcome of M‐protein screening program of multiple myeloma in China: A 7‐year cohort study

Abstract

Abstract Background To improve the early detection rate of multiple myeloma (MM), the M‐protein screening system has been performed in the hospital population at Zhongshan Hospital Fudan University since 2014, with electrophoretic‐based monoclonal immunoglobulin (M‐protein) screening integrated into the blood biochemistry panel. This study updated 7‐year follow‐up findings of MM patients diagnosed by screening‐driven and symptom‐driven approaches. Methods The retrospective study compared the characteristics and outcomes of patients diagnosed through two patterns by reviewing the plasma cell disease database from January 2014 to October 2021. The screening‐driven group included patients diagnosed through the screening system during workups of unrelated medical conditions or routine checkups. In contrast, patients who visited or were referred to the hematological department due to myeloma‐related end‐organ damage were categorized into the symptom‐driven group. Results There were 3,110,218 serum protein electrophoresis (SPEP) tests performed during 7 years, with 1.95% (60,609) patients yielding positive SPEP results. Of 911 confirmed MM cases (excluding concurrent amyloidosis), 366 were assigned to the screening‐driven group, while 545 were to the symptom‐driven group. Compared to the symptom‐driven group, the screening group had more IgG subtypes, earlier International Stage System stages, fewer disease‐related symptoms, lower ECOG scores, less extramedullary disease, a lower percentage of bone marrow plasma cells, and a lower level of lactate dehydrogenase. Frontline response results of two groups were similar. Patients detected through screening had a significantly improved median progression‐free survival (PFS) than the symptom‐driven group (62.2 vs. 24.9 months, p < 0.001, HR: 2.12, 95% CIs: 1.69–2.65), with median follow‐ups of 32.6 and 27.4 months. Furthermore, the median overall survival (OS) was significantly longer in patients of the screening group (not reached vs. 62.3 months, p < 0.001, HR: 2.49, 95% CIs: 1.81–3.41). After being adjusted for well‐acknowledged myeloma prognostic factors, the screening‐driven diagnostic pattern remained an independent prognostic factor indicating improved PFS and OS in MM patients. Conclusion Routine M‐protein screening for MM in the hospital population results in an earlier diagnosis and better patient outcomes.

Keywords

• cancer early detection
• frontline therapy
• M‐protein screening
• multiple myeloma
• patient outcomes